Medtronic begins trial of second generation stent:
This article was originally published in Clinica
Medtronic is starting a US clinical trial of its Talent LPS endoluminal stent for treating abdominal aortic aneurysms. The second-generation stent is made from thinner graft material than its predecessor, making it easier to implant, says Medtronic. The trial will involve 100 patients at 13 medical centres. The stent, which is made by the company's Sunrise, Florida-based subsidiary World Medical Manufacturing, has been available in Europe since November 1998.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.